FDA Clearance Tracker · P230009
Shield
Last checked: Nov 19, 2026Latest source record: Jul 26, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jul 26, 2024
Approved
Time to decision
504 days
Received Mar 10, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P230009
- Device name
- Shield
- Applicant
- Guardant Health, Inc.
- Applicant location
- Palo Alto, CA
- Received
- Mar 10, 2023
- Decided
- Jul 26, 2024
- Decision
- Approved
- Supplements
- 17 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
The Shield test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is intended for colorectal cancer screening in individuals at average risk of the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PHP. The earliest in FDA's data is P130017, decided Aug 11, 2014.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Guardant Health, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250027 · Decided May 19, 2026 · 292 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360 CDxPMA supplement
P200010-S026 · Decided Jan 15, 2026 · 176 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360 CDxPMA supplement
P200010-S021 · Decided Sep 25, 2025 · 325 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.